The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) yesterday recommended lowering the age for pneumococcal vaccination from 65 to 50 years old.

The vote in favor of the recommendation was 14 to 1. CDC Director Mandy Cohen, MD, endorsed the recommendation shortly after the ACIP meeting.

There are four pneumococcal vaccines available in the United States, including three pneumococcal conjugate vaccines (PCV15, PCV20, and PCV21), which cover different serotypes of Streptococcus pneumoniae, and the pneumococcal polysaccharide vaccine (PPSV23). The recommendation applies to PCVs and is for PCV-naïve adults aged 50 and older.

Increased risk of severe disease

Pneumococcal vaccination is also recommended for all children younger than 5 years old and older children with certain risk conditions. Pneumococcal disease is common in children, but older adults are at increased risk of severe illness and death.

The recommendation was made in part because of the high burden of pneumococcal disease in adults aged 50 to 64, particularly in those with high-risk conditions.

"Lowering the age for pneumococcal vaccination gives more adults the opportunity to protect themselves from pneumococcal disease at the age when risk of infection substantially increases," the CDC said in a statement. "Pneumococcal bacteria can cause serious illnesses, including pneumonia, meningitis, and bloodstream infections, and older adults are at increased risk for pneumococcal disease."

The one dissenting vote came from Jamie Loehr, MD, chair of ACIP's pneumococcal working group, who said he believed the recommendation should apply to PCV21 only.

"I think that PCV21 is a better vaccine," Loehr said during the ACIP meeting. "It covers many more serotypes for adults."

The CDC said adults aged 50 and older should speak with their healthcare provider to make sure they're up to date with pneumococcal vaccination.

After 8 days with no new cases, Rwanda's health ministry yesterday reported 1 new illness, raising the outbreak total to 63 cases, as the number of deaths held steady at 15. Two patients are still in treatment, and 46 have recovered.

At a media briefing with the Africa Centre for Disease Prevention and Control (Africa CDC), Rwanda Minister of Health Sabin Nsanzimana, MD, PhD, said the latest patient is a healthcare provider who works in the Marburg treatment center.

Patient had been vaccinated just days before

Though the man tested positive, he is doing well and doesn't have the usual Marburg symptoms. The patient had been vaccinated against Marburg a few days ago, and it's not clear if he was exposed to the virus before or after vaccination. 

The patient had no contacts outside the Marburg treatment center and had been living in a setting where the infection prevention and control protocol was high.

Nsanzimana said Rwanda has gone 10 days with no new Marburg deaths. He added that the overall picture is encouraging, though officials can't rule out other contacts reaching the symptomatic phase. The number of contacts under monitoring continues to decrease. "It's not yet over, but we have a great trend."

New genomic surveillance data published today in Morbidity and Mortality Weekly Report show that JN.1 and its descendants have been the most common SARS-CoV-2 variants in 2024, and they're still evolving.

The genomic surveillance was conducted by the Centers for Disease Control and Prevention's national SARS-CoV-2 genomic surveillance program, which previously detected both the Delta and Omicron variants. 

The new report covers detections from May 2023 through September 2024, from which researchers analyzed 208,357 SARS-CoV-2 sequences from 56 US jurisdictions.

In the summer of 2023, the authors write, multiple Omicron XBB descendants, including EG.5-like lineages, FL.1.5.1-like lineages, and HV.1 lineages reached more than 10% prevalence in the United States. 

JN.1 increased in winter of 2023

By the winter of 2023, however, JN.1 increasingly took hold. 

The JN.1 variant emerged in the United States and rapidly attained predominance nationwide.

"The JN.1 variant emerged in the United States and rapidly attained predominance nationwide, representing a substantial genetic shift," the authors write. "Surges in COVID-19 cases occurred in winter 2024 during the shift to JN.1 predominance.”

More surges were seen in the summer of 2024, the authors write, when cocirculation of JN.1 descendant lineages with identical substitutions, including the S31 deletion, R346T, and F456L emerged. These substitutions cause immune escape and increased transmissibility. 

"Continued monitoring to determine whether this pattern of divergent variant emergence followed by subsequent stepwise evolutionary changes continues will be important for updating COVID-19 vaccines and anticipating surges in COVID-19 activity," the authors conclude. 

A study of US adults who had community-acquired pneumonia (CAP) but were otherwise healthy found that broad-spectrum antibiotics were associated with increased risks of adverse drug events (ADEs), researchers reported yesterday in Clinical Infectious Diseases.

Using national data from a large insurance database, researchers from Washington University School of Medicine in St. Louis performed an active comparator new-user study to estimate the comparative risk of several individual ADEs between different outpatient antibiotic regimens for CAP among otherwise healthy, non-elderly adults. As the study authors note, uncertainty about the risks and benefits of different antibiotic regimens has resulted in a wide variation in antibiotic prescribing for CAP in outpatient settings, even though guidelines generally recommend narrow-spectrum agents when possible.

Increased risk of several ADEs

The researchers included 145,137 adults aged 18 to 64 who were diagnosed as having CAP from July 1, 2007, through November 30, 2019, and evaluated CAP-related antibiotic regimen and ADEs experienced 2 to 90 days after treatment. Fifty-two percent of patients received narrow-spectrum antibiotics (44% macrolide, 8% doxycycline) and 48% received broad-spectrum antibiotics (39% fluoroquinolone, 7% beta-lactam, 3% beta-lactam plus macrolide). The most common ADEs were nausea/vomiting/abdominal pain, rash/urticaria, non–Clostridioides difficile diarrhea, and vulvovaginal candidiasis/vaginitis

Compared with macrolide monotherapy, each broad-spectrum antibiotic was associated with increased risk of several ADEs. For example, beta-lactam was associated with increased risk of nausea/vomiting/abdominal pain (risk difference [RD] per 100, 0.32; 95% confidence interval [CI], 0.10 to 0.57), non–C difficile diarrhea (RD per 100, 0.46; 95% CI, 0.25 to 0.68), and vulvovaginal candidiasis/vaginitis (RD per 100, 0.36; 95% CI, 0.09 to 0.69). Doxycycline largely conferred similar risk of ADEs as macrolide monotherapy. 

The authors say the results of the study add to accumulating evidence suggesting that efforts to shift prescribing from broad-spectrum to narrower-spectrum agents may prevent ADEs.

"Ultimately, knowledge about antibiotic-related harms can help patients, prescribers, and stewardship programs make judicious decisions about antibiotic utilization," they wrote.